US4622601007
US4622601007
Iovance Biotherapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 263.502.000 | 164.070.000 | 60.6% |
| Cost of Revenue | 173.184.000 | 93.248.000 | 85.7% |
| Gross Profit | 90.318.000 | 70.822.000 | 27.5% |
| 488.531.000 | 466.100.000 | 4.8% | |
| Operating Income | -398.213.000 | -395.278.000 | 0.7% |
| Pretax Income | -393.049.000 | -375.005.000 | 4.8% |
| Net Income Common Stockholders | -390.978.000 | -372.177.000 | 5.1% |
| -- | -- | -- | |
| -- | -- | -- |